Chulabhorn Royal Academy Announces First Successful Production of “IMCRANIB 100” Cancer Drug
Chulabhorn Royal Academy has officially announced the successful domestic production of “IMCRANIB 100,” Thailand’s first targeted cancer therapy developed and manufactured entirely within the country. This milestone reflects the strategic vision and dedication of Professor Dr. Her Royal Highness Princess Chulabhorn Krom Phra Srisavangavadhana in advancing national healthcare and pharmaceutical self-reliance.
Chulabhorn Royal Academy has officially announced the successful domestic production of “IMCRANIB 100,” Thailand’s first targeted cancer therapy developed and manufactured entirely within the country. This milestone reflects the strategic vision and dedication of Professor Dr. Her Royal Highness Princess Chulabhorn Krom Phra Srisavangavadhana in advancing national healthcare and pharmaceutical self-reliance.
The initiative began in 2020 with the establishment of the Pharmaceutical Production Plant under Royal Initiative in Chonburi Province. The facility, certified under international GMDP PIC/S standards, functions as both a manufacturing site and a comprehensive research and development center aimed at reducing dependency on imported medications and strengthening national drug security.
IMCRANIB 100 is a targeted therapy that inhibits specific enzymes responsible for cancer cell growth, offering improved treatment outcomes with fewer side effects compared to traditional chemotherapy. It is indicated for several cancers, including chronic myeloid leukemia and gastrointestinal stromal tumors.
The local production of IMCRANIB 100 is expected to improve access to treatment, especially for patients not yet covered by national health funds. Chulabhorn Hospital will begin administering the drug in July 2025, marking a new era in precision oncology and pharmaceutical innovation in Thailand.
Source:
此类别中的文章由我们的编辑团队撰写，旨在让您了解最新的医疗保健和医疗旅游新闻。
